Ocrelizumab: a new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis

AM Stahnke, KM Holt - Annals of Pharmacotherapy, 2018 - journals.sagepub.com
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of
ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS). Data Sources: A …
被引用次数：32 相关文章

Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis

AM Stahnke, KM Holt - The Annals of pharmacotherapy, 2018 - pubmed.ncbi.nlm.nih.gov
Objective To review the pharmacology, pharmacokinetics, efficacy, and safety of
ocrelizumab, a new B-cell-targeted therapy for multiple sclerosis (MS). Data sources A …

Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.

AM Stahnke, KM Holt - The Annals of Pharmacotherapy, 2017 - europepmc.org
Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple
Sclerosis. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …